Talis Biomedical Corp Balance Sheet

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Balance Sheets

In millions of USD, except per-share amounts

	Q2 FY2024 As of Jun 30, 2024	Q1 FY2024 As of Mar 31, 2024	Q4 FY2023 As of Dec 31, 2023	Q3 FY2023 As of Sep 30, 2023	Q2 FY2023 As of Jun 30, 2023	Q1 FY2023 As of Mar 31, 2023	Q4 FY2022 As of Dec 31, 2022	Q3 FY2022 As of Sep 30, 2022	Q2 FY2022 As of Jun 30, 2022	Q1 FY2022 As of Mar 31, 2022	Q4 FY2021 As of Dec 31, 2021	Q3 FY2021 As of Sep 30, 2021	Q2 FY2021 As of Jun 30, 2021	Q1 FY2021 As of Mar 31, 2021
Assets
Current assets:
Cash and cash equivalents
Accounts receivable, net
Inventory, Net
Prepaid research and development expenses
Restricted cash
Grant receivables
Unbilled grant receivables
Prepaid expenses and other current assets
Total current assets
Property and equipment, net
Operating lease right-of-use-assets
Other long-term assets
Total assets
Liabilities and Stockholders Equity
Current liabilities:
Accounts payable
Accrued compensation
Accrued expenses and other current liabilities
Accrued liabilities
Operating lease liabilities, current portion
Total current liabilities

Operating lease liabilities, long-term portion
Total liabilities
Stockholders' equity:
Series 1 convertible preferred stock, $0.0001 par value - 60,000,000 shares authorized as of June 30, 2024 and December 31, 2023; 29,863,674 shares issued and outstanding as of June 30, 2024 and December 31, 2023; aggregate liquidation preference of $3 as of June 30, 2024 and December 31, 2023
Common stock, $0.0001 par value; 200,000,000 shares authorized as of June 30, 2024 and December 31, 2023; 1,822,153 and 1,821,986 shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectively
Additional paid-in capital
Accumulated deficit
Total stockholders' equity
Total liabilities and stockholders' equity

Comments